Some features of the coronavirus infection course in bronchial asthma patients

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The outbreak of a new coronavirus infection was officially recognized by the World Health Organization as a global pandemic since March 11, 2020. The pandemic is currently gradually receding, the number of patients is also steadily decreasing. However, these circumstances are not grounds to believe that the virus has been definitively and irrevocably defeated. For this reason, the world medical community is still concerned about the coronavirus’ impact on the course and outcome of various chronic bronchopulmonary diseases. Bronchial asthma has been recognized as one of the leading forms of human somatic pathology throughout the history of mankind and medicine. It is quite natural that the focus of the researchers' attention turned out to be questions about the SARS-CoV-2 virus’ impact on patients suffering from bronchial asthma, starting with the peculiarities of the course of combined pathology and ending with the peculiarities of therapy and subsequent rehabilitation. The issues of coronavirus infection and bronchial asthma pathogenesis were considered. The research data on some features of the development and course of a new coronavirus infection in patients with this profile were analyzed and summarized. The low coronavirus infection prevalence among patients with an allergic bronchial asthma form compared with other phenotypes is shown among such features, data on the effect of eosinophilia on the course of infection are presented, and the basic therapy’s positive effect using inhaled glucocorticosteroids and/or monoclonal antibodies (biological therapy) in severe asthma, is shown in the form of a protective effect that provides a lighter coronavirus infection course. The main features of patient management suffering from bronchial asthma in the conditions of a pandemic are the organization of stable medical control in online telemedicine once monthly, regular examinations in accordance with the severity of the course of the disease and the correction of basic therapy to achieve complete control over the course of asthma.

About the authors

Mikhail A. Kharitonov

Military medical academy of S.M. Kirov

Email: micjul11@yandex.ru
ORCID iD: 0000-0002-6521-7986
SPIN-code: 7678-2278

Doctor of Medical Sciences, Professor

Russian Federation, Saint Petersburg

Yulia S. Burkova

Military Medical Academy of S.M. Kirov

Author for correspondence.
Email: sjs81@mail.ru
ORCID iD: 0000-0002-0276-9863
SPIN-code: 8240-3729

Candidate of Medical Sciences

Russian Federation, Saint Petersburg

Vladimir V. Salukhov

Military Medical Academy of S.M. Kirov

Email: vlasaluk@yandex.ru
ORCID iD: 0000-0003-1851-0941
SPIN-code: 4531-6011

Doctor of Medical Sciences

Russian Federation, Saint Petersburg

Anastasia S. Sapronova

Military Medical Academy of S.M. Kirov

Email: sapronova.nastya@bk.ru
ORCID iD: 0000-0003-2742-7904
SPIN-code: 3901-5972
Russian Federation, Saint Petersburg

References

  1. Ochani RK, Asad A, Yasmin F, et al COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infections in Medicine. 2021;29(1):20–36.
  2. Fisun AYa, Aganov DS, Bazilevich SN. COVID-19 i zabolevaniya vnutrennikh organov: osobennosti vedeniya patsientov. Vremennye klinicheskie rekomendatsii. 2020. P. 131–144. (In Russ.).
  3. Salukhov VV, Kovalevskaya EA. Vitamin D is a strategic blow to coronavirus infection. Medical Council. 2020;(21):218–228. (In Russ.). doi: 10.21518/2079-701X-2020-21-218-228
  4. Broadhurst R, Peterson R, Wisnivesky JP, et al. Asthma in COVID-19 Hospitalizations: An Overestimated Risk Factor? Ann Am Thorac Soc. 2020;17(12):1645–1648. doi: 10.1513/AnnalsATS.202006-613RL
  5. Sunjaya AP, Allida SM, Di Tanna GL, Jenkins CR. Asthma and Coronavirus Disease 2019 Risk: a systematic review and meta-analysis. Eur Respir J. 2021;14(2):210. doi: 10.1183/13993003.01209-2021
  6. Caminati M, Vultaggio A, Matucci A, et al. Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity. Respir Med. 2021;176(7):106261. doi: 10.1016/j.rmed.2020.106261
  7. Avdeev SN, Nenasheva NM, Zhudenkov KV, et al. Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation. Pulmonologiya. 2018;28(3):341–358. (In Russ.). doi: 10.18093/0869-0189-2018-28-3-341-358
  8. Salukhov VV, Kharitonov MA, Kryukov EV, et al. Topical issues of diagnostics, examination and treatment of patients with COVID-19-associated pneumonia in different countries and continents. Medical Council. 2020;(21):96–102. (In Russ.). doi: 10.21518/2079-701X-2020-21-96-102
  9. Rudakov JV, Mitin JA. The immunology special features of bronchial asthma in the patients, with the debut of disease at the age are older than 60 years. Bulletin of the Russian Military Medical Academy. 2009;(1):94–96. (In Russ.).
  10. Trushina EYu, Kostina EM, Orlova EA. Patients with bronchial asthma who have undergone COVID-19. Farmateka. 2021;(5):76–80. (In Russ.). doi: 10.18565/pharmateca.2021.5.76-80
  11. Fedoseev GB, Trofimov VI. Bronkhial'naya astma. Saint Petersburg: Normedizdat, 2006. 308 p. (In Russ.).
  12. Kharitonov MA, Salukhov VV, Kryukov EV, et al. Viral pneumonia: a new look at an old problem (review). Medical Council. 2021;(16): 60–77. (In Russ.). doi: 10.21518/2079-701X-2021-16-60-77
  13. Kalinichenko UYu, Shvarts VD. Koronavirusnaya infektsiya COVID-19 I BA. Forcipe. 2021;4(1):833–834. (In Russ.).
  14. Gaisina AR, Shilovskiy IP, Nikonova AA, et al. The study of balance of Th1/Th2 immune response during virus-induced asthma exacerbation. Russian Journal of Allergy. 2016;13(4–5):20–28. (In Russ.). doi: 10.36691/RJA347
  15. Asiryn EG, Matyuschenko OV, Matsuk ON. Pathogenetic aspects of bronchial asthma. Maternal and child health. 2020;(1):102–107. (In Russ.).
  16. Tsai S-C, Lu C-C, Bau D-T, et al. Approaches towards fighting the COVID-19 pandemic (Review). Int J Mol Med. 2021;47(1):3–22. doi: 10.3892/ijmm.2020.4794
  17. Osipova VV, Osipova GL, Zaryanova EA, Terekhov DV. Asthma and COVID-19: Аn overview of the guidelines for the management of asthma patients during the COVID-19 pandemic. Pulmonologiya. 2021;31(5): 663–670. (In Russ.). doi: 10.18093/0869-0189-2021-31-5-663-670
  18. Nenasheva NM. Fenotipy bronkhial'noi astmy i vybor terapii. Prakticheskaya pul'monologiya. 2014;(2):2–11. (In Russ.).
  19. Ovsyannikov ES, Аvdeev SN, Budnevskiy AV, et al. Bronchial Asthma and COVID-19: Comorbidity Issues. Tuberculosis and Lung Diseases. 2021;99(9):6–14. (In Russ.). doi: 10.21292/2075-1230-2021-99-9-6-14
  20. Choi YJ, Park J-Y, Lee HS, et al. Effect of asthma and asthma medication on the prognosis of patients with COVID-19. Eur Respir J. 2021;57(3):2226. doi: 10.1183/13993003.02226-2020
  21. Anka AU, Tahir MI, Abubakar SD, et al. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. Scand J Immunol. 2020;6(2):1298. doi: 10.1111/sji.12998
  22. Val'chuk IN. Sovremennye problemy ostrykh respiratornykh infektsii i bronkhial'noi astmy: sbornik nauchnykh trudov Belorusskogo gosudarstvennogo meditsinskogo universiteta. T. 1. Minsk: GU RNMB, 2011. P. 7. (In Russ.).
  23. Nicholson K, Kent J, Ireland D. Respiratory viruses and exacerbations of asthma in adults. BMJ . 1993;3079(6910):982–986. doi: 10.1136/bmj.307.6910.982
  24. Ayoubkhani D, Khunti K, Nafilyan V, Maddox T. Post-covid syndrome in individuals admitted to hospital with COVID-19: retrospective cohort study. BMJ. 2021;372(49):693. doi: 10.1136/bmj.n693
  25. Global Initiative for Asthma. GINA guidance about COVID-19 and asthma 2022. 223 р.
  26. Green I, Merzon E, Vinker S, Golan-Conen A. COVID-19 Susceptibility in Bronchial Asthma. J Allergy Clin Immunol Pract. 2021;9(2):684–692. doi: 10.1016/j.jaip.2020.11.020
  27. Izquierdo JL, Almonacid C, Gonzalez Y, et al. The impact of COVID-19 on patients with asthma. Eur Respir J. 2021;57(3):2142. doi: 10.1183/13993003.03142-2020
  28. Rosenberg HF, Foster PS. Eosinophils and COVID-19: diagnosis, prognosis, and vaccination strategies. Semin Immunopathol. 2021;43(3):383–392. doi: 10.1007/s00281-021-00850-3
  29. Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020;75(11):2829–2845. doi: 10.1111/all.14429
  30. Skevaki C, Karsonova A, Karaulov A, et al. Asthma-associated risk for COVID-19 development. J Allergy Clin Immunol. 2020;146(6):1295–1301. doi: 10.1016/j.jaci.2020.09.017
  31. Wark PAB, Pathinayake PS, Eapen MS, Sohal SS. Asthma, COPD and SARS-CoV-2 infection (COVID-19): potential mechanistic insights. Eur Respir J. 2021;58(2):2100920. doi: 10.1183/13993003.00920-2021
  32. Gagne M, Cheung JLS, Kouri A, et al. A patient decision aid for mild asthma: Navigating a new asthma treatment paradigm. Respir Med. 2021:106568. doi: 10.1016/j.rmed.2021.106568
  33. Davido B, Partouche B, Jaffal K, et al. Eosinopenia in COVID-19: What we missed so far? J Microbiol Immunol Infect. 2021;54(5): 1006–1007. doi: 10.1016/j.jmii.2021.01.013
  34. Lieberman-Cribbin W, Rapp J, Alpert N, et al. The Impact of Asthma on Mortality in Patients With COVID-19. Chest. 2020;158(6):2290–2291. doi: 10.1016/j.chest.2020.05.575
  35. Gasmi A, Peana M, Pivina L, et al. Interrelations between COVID-19 and other disorders. Clin Immunol. 2021;224(28):108. doi: 10.1016/j.clim.2020.108651
  36. Peredel'skaya MYu, Nenasheva NM. BA i COVID-19: chto izvestno o sochetanii dvukh diagnozov u odnogo bol'nogo. Astma i allergiya. 2021;(2):3–8. (In Russ.).
  37. Zhang J-J, Dong X, Cao Y-Y. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75(7): 1730–1741. doi: 10.1111/all.14238
  38. Zhao L, Zhang Y-P, Yang X, Liu X. Eosinopenia is associated with greater severity in patients with coronavirus disease 2019. Allergy. 2021;76(2):562–564. doi: 10.1111/all.14455
  39. Yamaya M, Nishimura H, Deng X, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020;58(3):155–168. doi: 10.1016/j.resinv.2019.12.005
  40. Agusti A, Torres F, Faner R. Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19. Lancet Respir Med. 2021;9(7):682–683. doi: 10.1016/S2213-2600(21)00171-5
  41. Khludova LG. BA i COVID-19. Astma i allergiya. 2020;(1):3–5. (In Russ.).
  42. Hojo M, Terada-Hirashima J, Sugiyama H. COVID-19 and bronchial asthma: current perspectives. Global Health and Medicine. 2021;3(2):67–72. doi: 10.35772/ghm.2020.01117
  43. Johnston SL. Asthma and COVID-19: is asthma a risk factor for severe outcomes? Allergy. 2020;75(7):1543–1545. doi: 10.1111/all.14348
  44. Riegel B, Westland H, Iovino P, et al. Characteristics of self-care interventions for patients with a chronic condition: A scoping review. Int J Nurs Stud. 2021;116(2):103713. doi: 10.1016/j.ijnurstu.2020.103713
  45. Eger K, Bel EH. Asthma and COVID-19: do we finally have answers? Eur Respir J. 2021;57(3):2004451. doi: 10.1183/13993003.04451-2020
  46. Heffler E, Detoraki A, Contoli M, et al. COVID-19 in Severe Asthma Network in Italy (SANI) patients: clinical features, impact of comorbidities and treatments. Allergy. 2020;15(4):111–123. doi: 10.22541/au.159335800.09668428
  47. Denneny EK, Garthwaite HS, Heightman MJ, Porter JC. A Role for Steroids in COVID-19-associated Pneumonitis at Six-Week Follow-Up? Ann Am Thorac Soci. 2021;18(6):1082–1083. doi: 10.1513/AnnalsATS.202101-048LE
  48. Tabatabaian F, Ledford DK. Omalizumab for severe asthma: toward personalized treatment based on biomarker profile and clinical history. J Asthma Allergy. 2018;11(5):53–61. doi: 10.2147/JAA.S107982
  49. Petrov DV, Belevskii AS. Vedenie patsientov s bronkhial'noi astmoi v usloviyakh pandemii COVID-19. Astma i allergiya. 2020;(1):6–11. (In Russ.).
  50. Fomina DS, Serdotetskova SA, Ivanova MS, et al. Management of patients with COVID-19 and asthma: literature review and clinical experience of the authors. Prakticheskaya pul'monologiya. 2020;(2):3–15. (In Russ.).
  51. Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021;9(7):763–772. doi: 10.1016/S2213-2600(21)00160-0

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Kharitonov M.A., Burkova Y.S., Salukhov V.V., Sapronova A.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies